Concurrent trials are ongoing to evaluate the efficacy of enoblituzumab in combination with the retifanlimab (anti-PD-1) or tebotelimab molecule designed to target LAG-3 and PD-1 in patients with recurrent metastatic HNSCC (NCT04634825). Here, PDCD1 is linked to head and neck squamous cell carcinoma.